\[Federal Register: June 22, 2000 (Volume 65, Number 121)\]

\[Notices\]

\[Page 38832-38833\]

From the Federal Register Online via GPO Access \[wais.access.gpo.gov\]

\[DOCID:fr22jn00-79\]

=======================================================================

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Food and Drug Administration

National Institutes of Health

Draft Public Health **Action** **Plan** to Combat Antimicrobial

Resistance

AGENCIES: Centers for Disease Control and Prevention (CDC), Food and

Drug Administration (FDA), National Institutes of Health (NIH),

Department of Health and Human Services (HHS).

**ACTION**: Notice of availability and request for public comment.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

SUMMARY: This notice announces the availability of a document for

public comment entitled \`\`Draft Public Health **Action** **Plan** to
Combat

Antimicrobial Resistance.\'\' This **Action** **Plan** provides a
blueprint for

comprehensive and coordinated efforts of Federal agencies

\[\[Page 38833\]\]

in addressing the emergence of antimicrobial resistance.

DATES: Comments must be submitted in writing on or before August 4,

2000\.

FOR FURTHER INFORMATION CONTACT: Requests for copies of the Draft

Public Health **Action** **Plan** to Combat Antimicrobial Resistance
should be

made to the Office of Health Communication, National Center for

Infectious Diseases, Centers for Disease Control and Prevention,

Mailstop C-14, 1600 Clifton Road, Atlanta, GA 30333; fax: 404-639-5489;

or e-mail: ncid@cdc.gov; or Internet URL:
[http://](http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.cdc.gov.drugresistance/actionplan/)

[www.cdc.gov.drugresistance/actionplan/](http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.cdc.gov.drugresistance/actionplan/).

ADDRESSES: Comments on the Draft Public Health **Action** **Plan** to
Combat

Antimicrobial Resistance should be submitted to the Office of Health

Communication, National Center for Infectious Diseases, Centers for

Disease Control and Prevention, Mailstop C-14, 1600 Clifton Road,

Atlanta, GA 30333; fax: 404-639-5489; e-mail: aractionplan@cdc.gov; or

Internet URL:
[http://www.cdc.gov.drugresistance/actionplan/](http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.cdc.gov.drugresistance/actionplan/).

SUPPLEMENTARY INFORMATION: Antimicrobial resistance is an emerging

public health threat that has been identified as an important priority

by the Institute of Medicine and other expert bodies and is the subject

of several proposed Healthy People 2010 goals relative to Infectious

Diseases. In late 1998, CDC, FDA, and NIH recognized the need for

better coordination and stimulation of the Federal response to this

threat. In addition, in December of 1998, Senators William Frist and

Edward Kennedy held a roundtable discussion on antimicrobial

resistance, and a hearing was held in February 1999. Shortly

thereafter, an Interagency Task Force on Antimicrobial Resistance was

created to develop a Public Health **Action** **Plan** to Combat
Antimicrobial

Resistance. The Task Force is co-chaired by CDC, FDA, and NIH, and

includes the Health Care Financing Administration, the Health Resources

and Services Administration, Agency for Healthcare Research and

Quality, the Department of Agriculture, the Department of Defense, the

Department of Veterans Affairs, and the Environmental Protection

Agency.

The Draft Public Health **Action** **Plan** to Combat Antimicrobial

Resistance, Part I focuses on domestic issues. Since AR transcends

national borders and requires a global approach to its prevention and

control, Part II of the **plan**, to be developed subsequently, will

identify actions that more specifically address international issues.

The **Plan** includes a summary and a list of issues, goals, and 87
**action**

items addressing four focus areas: Surveillance, Prevention and

Control, Research, and Product Development. For each **action** item,

\`\`coordinator\'\' and \`\`collaborator\'\' agencies/departments and
timelines

are specified. The Interagency Task Force will monitor, and if

necessary, update the **Plan**, during the coming years.

Jeffrey P. Koplan,

Director, Centers for Disease Control and Prevention (CDC).

Ruth Kirschstein,

Acting Director, National Institutes of Health (NIH).

Jane E. Henney,

Commissioner, Food and Drug Administration (FDA).

\[FR Doc. 00-15847 Filed 6-21-00; 8:45 am\]

BILLING CODE 4160-18-P 4140-01-P 4150-04-P